rain therapeutics is a san francisco bay area-based biotechnology company, focused on developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver.
Company profile
Ticker
RAIN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Rain Therapeutics Inc.
SEC CIK
Corporate docs
Subsidiaries
Rain Oncology Australia Pty Ltd ...
IRS number
821130967
RAIN stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
5 Feb 24
EFFECT
Notice of effectiveness
31 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 24
POS AM
Prospectus update (post-effective amendment)
26 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
26 Jan 24
SC 14D9/A
Tender offer solicitation (amended)
26 Jan 24
SC TO-T/A
Third party tender offer statement (amended)
26 Jan 24
25-NSE
Exchange delisting
26 Jan 24
Transcripts
RAIN
Earnings call transcript
2023 Q2
10 Aug 23
RAIN
Earnings call transcript
2023 Q1
11 May 23
RAIN
Earnings call transcript
2022 Q4
9 Mar 23
RAIN
Earnings call transcript
2022 Q3
10 Nov 22
RAIN
Earnings call transcript
2022 Q2
6 Aug 22
RAIN
Earnings call transcript
2022 Q1
8 May 22
RAIN
Earnings call transcript
2021 Q4
4 Mar 22
RAIN
Earnings call transcript
2021 Q3
11 Nov 21
RAIN
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Samsara BioCapital, L.P.
14 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13D/A
TANG CAPITAL PARTNERS LP
2 Feb 24
4
KEVIN C TANG
2 Feb 24
4
MARK N LAMPERT
29 Jan 24
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
29 Jan 24
4
Stefani Wolff
26 Jan 24
4
Peter Radovich
26 Jan 24
4
Tran Nguyen
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.31 mm | 37.31 mm | 37.31 mm | 37.31 mm | 37.31 mm | 37.31 mm |
Cash burn (monthly) | 921.33 k | 210.17 k | 2.69 mm | 6.38 mm | 2.33 mm | 5.48 mm |
Cash used (since last report) | 6.15 mm | 1.40 mm | 17.98 mm | 42.62 mm | 15.57 mm | 36.58 mm |
Cash remaining | 31.16 mm | 35.91 mm | 19.34 mm | -5.31 mm | 21.74 mm | 732.09 k |
Runway (months of cash) | 33.8 | 170.9 | 7.2 | -0.8 | 9.3 | 0.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 61 |
Opened positions | 9 |
Closed positions | 15 |
Increased positions | 13 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 13.36 bn |
Total shares | 28.42 mm |
Total puts | 500.00 |
Total calls | 19.80 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Partners | 3.74 mm | $4.64 mm |
Tang Capital Management | 3.74 mm | $3.22 bn |
Biotechnology Value Fund L P | 3.53 mm | $4.16 mm |
BVF | 3.53 mm | $3.04 bn |
Cormorant Global Healthcare Master Fund | 2.73 mm | $0.00 |
Samsara BioCapital | 2.26 mm | $35.72 mm |
Samsara BioCapital | 2.03 mm | $1.75 bn |
Boxer Capital | 1.15 mm | $992.98 mm |
BLK Blackrock | 1.02 mm | $875.06 mm |
Vanguard | 902.66 k | $777.92 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jan 24 | Avanish Vellanki | Common Stock, par value $0.001 per share | Dispose U | No | No | 0 | 2,550,910 | 0.00 | 0 | |
26 Jan 24 | Avanish Vellanki | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8.02 | 152,150 | 1.22 mm | 0 |
26 Jan 24 | Avanish Vellanki | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.21 | 133,250 | 161.23 k | 0 |
26 Jan 24 | Avanish Vellanki | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.21 | 266,500 | 322.47 k | 0 |
26 Jan 24 | Avanish Vellanki | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.3 | 304,485 | 2.83 mm | 0 |
26 Jan 24 | Avanish Vellanki | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8.02 | 30,150 | 241.80 k | 0 |
26 Jan 24 | Avanish Vellanki | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4 | 31,832 | 127.33 k | 0 |
26 Jan 24 | Avanish Vellanki | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.3 | 14,115 | 131.27 k | 0 |
26 Jan 24 | Robert Doebele | Common Stock, par value $0.001 per share | Dispose U | No | No | 0 | 476,827 | 0.00 | 0 | |
26 Jan 24 | Robert Doebele | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.01 | 59,642 | 716.30 k | 0 |